Asain market This may help to understand the importance of the deals made by PLI with WIBP and Hematech.
https://www.imapac.com/index.php?page=BioplasmaWorldAsia2012Concept
In 2010 the global therapeutic blood products industry was valued at nearly $16 billion in 2010 and is expected to reach $26 billion in 2015 rate (CAGR) of 10.8. The plasma product market in Asia and China in particularly are expected to grow at a higher rate of 15-20% CAGR reflecting the region’s rapid growth, compared to more established markets in Europe and the USA.
According to a 2011 article in the ISBT, 6 million litres a year of Plasma Asia currently fractionates is too low to meet its needs. Asia’s fractionation capacity represents 20% of the world’s fractionation capacity BUT its population is 60% of the world’s. The imbalance between capacity and population is one of the key drivers for growth in the next decade.
Currently there are around domestic 35 fractionators in Asia who operate in Australia, China, India, Japan, republic of Korea and Thailand. All other Asian nations have to rely on contract fractionation to secure Plasma products for their healthcare systems. This has prompted Countries like Indonesia, Malaysia, Vietnam and Taiwan to investigate investments into domestic fractionation facilities, to secure their own supplies of plasma products which can be vulnerable to market fluctuations.
With regional demand rising several new fractionation facilities have been planned in both China and India, in addition to the countries seeking to invest into domestic fractionation facilities.
Bioplasma World Asia 2012 will be attended by decision makers from regional and international fractionators. It's your one stop solution to reach out to Asia’s plasma industry